Pfizer Inc., one of the trifecta pharmaceutical companies nmanufacturing COVID-19 vaccines, is acquiring another large pharma ncompany that is conduction clinical trials on a variety of drugs, nincluding one that is examining the efficacy of cannabinoids.
PRINCETON, N.J., Dec. 3, 2020 /PRNewswire/ -- WCG today announced its acquisition of Trifecta Clinical, a proven leader in technology-enabled clinical trial solutions, including its comprehensive site communication platform InvestigatorSpace®, virtual training programs and safety documentation services.
Trifecta Clinical, a leading global provider of online clinical investigator training, is excited to announce the launch of Voices in Life Sciences (VLS) at the 2014 Disruptive Innovations in Boston.n“Last year at Disruptive Innovations I presented the idea of applying processes and methods used in Independent film to the training challenges we face in clinical development,” said Dave Young, CEO of Trifecta. “Julie Crawford, our Director of Operations, led an interdisciplinary team to take this crazy idea and make it a reality. I’m honored to work with such an incredible team.”
Trifecta Clinical, a US-based company specialising in both live and online training of clinical research investigators, has joined the board of directors of the Asia Training Consortium (ATC).nnFormed in October 2011 in Shanghai, China, the ATC is a group of pharmaceutical companies and clinical research organisations, plus one regional association, that are pooling their resources to deliver quality training courses for clinical research professionals in the Asia Pacific region.